Dexmedetomidine in preeclamptic patients undergoing caesarean section under general anesthesia

El-Arab, Nosaiba K Ezz; El-Hawary, Salama I; Elzeftawy, Ashraf Elsayed; Mohammed, Rabab

doi:10.4103/tmj.tmj_35_17

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The additional properties of dex-medetomidine, such as anxiolysis, reducing anesthetic requirement when used as an adjuvant, and cardiovascular stability, can be attractive factors when considering the use of dexmedetomidine in pregnant women [2]. Several trials of dexmedetomidine have been conducted in the obstetrics field, such as application as an adjuvant analgesic with remifentanil during labor [3], as an adjuvant during general anesthesia for cesarean sections in normal pregnancies [4], in a parturient with preeclampsia [5], or as the sole sedative during cesarean section under spinal anesthesia [6]. However, there are some concerns for the use of dexmedetomidine for obstetric anesthesia, such as changes in uterine contractions after labor and fetal effects by placental transfer [2].…”

Section: Introductionmentioning

confidence: 99%

Clinically relevant concentrations of dexmedetomidine may reduce oxytocin-induced myometrium contractions in pregnant rats

Kim

Jang

et al. 2020

Anesth Pain Med

View full text Add to dashboard Cite

Background: Recently, there have been some trials to use dexmedetomidine in the obstetric field but concerns regarding the drug include changes in uterine contractions after labor. We aimed to evaluate the effects of dexmedetomidine on the myometrial contractions of pregnant rats.Methods: In a pilot study, the contraction of the myometrial strips of pregnant Sprague-Dawley rats in an organ bath with oxytocin at 1 mU/ml was assessed by adding dexmedetomidine from 10-6 to 10-2 M accumulatively every 20 min, and active tension and the number of contractions were evaluated. Then, changes in myometrial contractions were evaluated from high doses of dexmedetomidine (1.0 × 10−4 to 1.2 × 10−3 M). The effective concentrations (EC) for changes in uterine contractions were calculated using a probit model.Results: Active tension and the number of contractions were significantly decreased at 10-3 M and 10-4 M dexmedetomidine, respectively (P < 0.05). A complete loss of contractions was seen at 10-2 M. Dexmedetomidine (1.0 × 10−4 to 1.2 × 10−3 M) decreased active tension and the number of contractions in a concentration-dependent manner. The EC95 of dexmedetomidine for inhibiting active tension and the number of contractions was 5.16 × 10-2 M and 2.55 × 10-5 M, respectively.Conclusions: Active tension of the myometrium showed a significant decrease at concentrations of dexmedetomidine higher than 10-3 M. Thus, clinical concentrations of dexmedetomidine may inhibit uterine contractions. Further research is needed for the safe use of dexmedetomidine in the obstetrics field.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinically relevant concentrations of dexmedetomidine may reduce oxytocin-induced myometrium contractions in pregnant rats

Kim

Jang

et al. 2020

Anesth Pain Med

View full text Add to dashboard Cite

show abstract

Unique Pain Management Needs for Pregnant Women with Pre-existing PTSD and Other Mental Health Disorders

Vogel

2021

Curr Anesthesiol Rep

View full text Add to dashboard Cite

Dexmedetomidine in preeclamptic patients undergoing caesarean section under general anesthesia

Cited by 2 publications

References 5 publications

Clinically relevant concentrations of dexmedetomidine may reduce oxytocin-induced myometrium contractions in pregnant rats

Clinically relevant concentrations of dexmedetomidine may reduce oxytocin-induced myometrium contractions in pregnant rats

Unique Pain Management Needs for Pregnant Women with Pre-existing PTSD and Other Mental Health Disorders

Contact Info

Product

Resources

About